The company organized the preparation of the 2023 comprehensive budget asset inventory work to start at the same time.
Release time:
2022-11-14
News from our newspaper Group Company recently issued a notice to start the comprehensive budget preparation for 2023 , and the annual inventory of the company's assets was also started at the same time.
The preparation of the comprehensive budget is to improve the company's management level, optimize resource allocation, improve internal control, and ensure the company's sustainable and stable development. According to the company's strategic development plan and comprehensive budget management system, the scope of budgeting includes group companies, wholly-owned subsidiaries and holding subsidiaries. The overall budget follows the principle of "top-down, bottom-up, combination of top and bottom, group preparation and level-by-level summary". Each enterprise budget management office shall, within the specified time, refer to the actual production and operation situation in 2022 and combine with the budget summary of "10 (month) 2 (month), as well as the prediction of the national economic macro situation and market environment in 2023 , and the preparation of business budget, capital budget and financial budget according to the principle of advanced nature against the overall deployment and arrangement of the group company.
In order to make the annual comprehensive budget more practical and effective, the company requires all enterprises to decompose the annual budget into months or quarters according to the production cycle and the seasonal changes of the actual light and busy seasons, and form the profit budget preparation of the corresponding stage; When budgeting the period expenses, the zero-based budget method shall be followed, and the period expenses shall be based on their different nature, according to fixed costs, variable costs, mixed costs are organized separately to control costs more effectively. In addition, in order to better assess the reasonableness of budget formulation, each unit is required to prepare its budget by comparing the budgeted amounts of related production, units, and costs with the actual amounts of 2022 , and to explain the changes. After the budget preparation is submitted to the Group for review and approval, it will be broken down and implemented in the first quarter of 2023 .
In addition, in order to strengthen asset management, ensure the quality of accounting information, and ensure the authenticity, safety and integrity of the company's assets, it was decided to conduct a comprehensive asset inventory before the end of 2022 12 . All accounting units included in the scope of the Group's consolidated financial statements are the subject of this asset inventory. Each unit shall set up an asset inventory team composed of personnel from relevant departments and designate a person in charge, and the Group Finance Department and audit institution will send personnel to supervise the inventory.
The annual asset inventory will be conducted in two stages. From the date of issuance of the notice to the end of 11 , the inventory will cover fixed assets, construction in progress, intangible assets and right-to-use assets. The second stage will end from the first stage to the end of 12 , including monetary funds, inventory, bills, securities and other assets. Each subordinate enterprise and professional company will summarize the inventory list and results at the end of each stage and report to the Group Finance Department for filing. Inventory gains, inventory losses and other property that gives rise to losses will be financially treated in accordance with relevant regulations and company systems.
(Reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page